Lab
Biocorp Clinical Lab INC
Biocorp Clinical Lab INC was paid $18.69M by Medicaid between Jan 2018 and Dec 2024, across 148 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 9.7% of everything it billed.
33Billing provider infoBIOCORP CLINICAL LAB INC
WHITTIER, CA 90605
WHITTIER, CA 90605
33aNPI1245275106assigned 06/17/2006
33bProvider typeClinical Medical Laboratory
28Total paid$18.69M
24GClaims1,420,001
24DCodes billed148
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#49 of 561
Median peer was paid$222K
This provider vs. median84×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 182,510 | $1.90M | |
| 2019 | 105,705 | $1.25M | |
| 2020 | 109,300 | $1.57M | |
| 2021 | 185,983 | $2.94M | |
| 2022 | 198,304 | $4.22M | |
| 2023 | 252,362 | $3.63M | |
| 2024incomplete | 385,837 | $3.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 9.7% | 63,457 | 59,106 | $1.81M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 9.7% | 63,623 | 59,293 | $1.81M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.6% | 29,767 | 13,449 | $1.79M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.1% | 4,193 | 4,058 | $946K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.9% | 48,393 | 45,028 | $917K |
| 87150 | 4.5% | 4,092 | 3,951 | $833K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.4% | 49,975 | 48,824 | $815K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.8% | 14,956 | 13,968 | $719K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.1% | 62,019 | 60,020 | $585K |
| 80061 | Lipid panel | 2.8% | 68,215 | 66,495 | $517K |
| 80053 | Comprehensive metabolic panel | 2.1% | 71,068 | 67,625 | $400K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 84,022 | 79,791 | $376K |
136 more codes
| 83036 | Hemoglobin; glycosylated (A1C) | 2.0% | 63,032 | $367K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.9% | 2,340 | $362K |
| 82607 | 1.8% | 34,993 | $344K | |
| 80055 | 1.5% | 8,654 | $288K | |
| 87481 | 1.5% | 6,450 | $280K | |
| 84439 | 1.4% | 41,723 | $253K | |
| 84480 | 1.3% | 22,233 | $242K | |
| 80050 | General health panel | 1.2% | 6,252 | $232K |
| 86003 | 1.2% | 1,191 | $230K | |
| 86481 | 1.1% | 3,260 | $206K | |
| 86592 | 1.0% | 54,022 | $191K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16,294 | $175K |
| 84702 | <1% | 13,023 | $154K | |
| 80074 | <1% | 5,000 | $141K | |
| 84153 | <1% | 13,015 | $135K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,383 | $132K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,076 | $132K |
| 83540 | <1% | 31,079 | $126K | |
| 82977 | <1% | 19,543 | $115K | |
| 84481 | <1% | 11,674 | $109K | |
| 86431 | <1% | 26,781 | $108K | |
| 87653 | <1% | 4,406 | $105K | |
| 86769 | <1% | 3,040 | $103K | |
| 87500 | <1% | 4,223 | $103K | |
| 87640 | <1% | 4,501 | $103K | |
| 87641 | <1% | 4,464 | $102K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,706 | $101K |
| 84550 | <1% | 34,307 | $89K | |
| 87186 | <1% | 15,032 | $86K | |
| 81001 | <1% | 44,170 | $86K | |
| 87088 | <1% | 17,313 | $82K | |
| 83735 | <1% | 20,191 | $81K | |
| 88142 | <1% | 4,967 | $81K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,765 | $78K |
| 86696 | <1% | 4,233 | $73K | |
| 81513 | <1% | 685 | $72K | |
| 82728 | <1% | 10,964 | $65K | |
| 86762 | <1% | 5,574 | $64K | |
| 85651 | <1% | 33,136 | $61K | |
| 82105 | <1% | 1,767 | $58K | |
| 82746 | <1% | 11,916 | $57K | |
| 86803 | <1% | 4,872 | $51K | |
| 84403 | <1% | 2,668 | $50K | |
| 86695 | <1% | 4,263 | $50K | |
| 86235 | <1% | 1,340 | $46K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,427 | $41K |
| 87340 | <1% | 5,193 | $40K | |
| 82043 | <1% | 12,155 | $37K | |
| 82950 | <1% | 9,230 | $35K | |
| 82570 | <1% | 12,234 | $34K | |
| 82670 | <1% | 1,477 | $34K | |
| 87081 | <1% | 5,996 | $31K | |
| 83001 | <1% | 2,058 | $31K | |
| 86140 | <1% | 11,267 | $30K | |
| 86694 | <1% | 3,063 | $30K | |
| 86317 | <1% | 3,165 | $30K | |
| 86038 | <1% | 5,843 | $30K | |
| 86200 | <1% | 7,018 | $29K | |
| 86301 | <1% | 2,653 | $27K | |
| 99000 | <1% | 7,682 | $27K | |
| 84144 | <1% | 1,464 | $25K | |
| 83002 | <1% | 1,573 | $24K | |
| 87631 | <1% | 427 | $24K | |
| 82951 | <1% | 2,245 | $23K | |
| 84146 | <1% | 1,499 | $23K | |
| 86304 | <1% | 1,592 | $20K | |
| 84100 | <1% | 7,958 | $19K | |
| 83550 | <1% | 8,182 | $19K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 398 | $18K |
| 86063 | <1% | 5,742 | $18K | |
| 82785 | <1% | 1,140 | $17K | |
| 82947 | <1% | 5,789 | $17K | |
| 88312 | <1% | 856 | $15K | |
| 86225 | <1% | 1,462 | $15K | |
| 84270 | <1% | 960 | $14K | |
| 87210 | <1% | 3,856 | $14K | |
| 83690 | <1% | 3,325 | $14K | |
| 84436 | <1% | 4,570 | $13K | |
| 82150 | <1% | 4,012 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,481 | $11K |
| 86376 | <1% | 1,842 | $11K | |
| 85730 | <1% | 3,453 | $9K | |
| 88112 | <1% | 708 | $9K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 229 | $9K |
| 85014 | <1% | 3,551 | $7K | |
| 85610 | <1% | 4,428 | $7K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 450 | $7K |
| 87077 | <1% | 1,021 | $6K | |
| 87070 | <1% | 1,103 | $6K | |
| 85018 | <1% | 3,099 | $6K | |
| 82952 | <1% | 1,780 | $6K | |
| 82378 | <1% | 1,698 | $5K | |
| 84703 | <1% | 834 | $5K | |
| 85044 | <1% | 5,383 | $5K | |
| 82270 | <1% | 2,128 | $4K | |
| 86704 | <1% | 708 | $4K | |
| 88141 | <1% | 466 | $4K | |
| 82550 | <1% | 2,808 | $4K | |
| 82248 | <1% | 3,972 | $4K | |
| 86850 | <1% | 1,364 | $3K | |
| 86677 | <1% | 392 | $3K | |
| 86141 | <1% | 1,955 | $3K | |
| 86800 | <1% | 603 | $3K | |
| 86787 | <1% | 230 | $3K | |
| 80076 | <1% | 554 | $2K | |
| 86708 | <1% | 427 | $2K | |
| 86901 | <1% | 916 | $2K | |
| 84479 | <1% | 670 | $2K | |
| 88342 | <1% | 25 | $2K | |
| 87625 | <1% | 40 | $1K | |
| 86171 | <1% | 91 | $1K | |
| 86900 | <1% | 511 | $1K | |
| 88164 | <1% | 117 | $1K | |
| 86705 | <1% | 101 | $998.18 | |
| 86060 | <1% | 200 | $812.53 | |
| 83090 | <1% | 716 | $779.76 | |
| 82172 | <1% | 667 | $715.69 | |
| 81025 | <1% | 196 | $687.66 | |
| 83615 | <1% | 728 | $600.93 | |
| 82310 | <1% | 239 | $599.67 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 405 | $578.53 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,733 | $464.96 |
| 88341 | <1% | 12 | $353.50 | |
| 82565 | <1% | 342 | $261.48 | |
| 82247 | <1% | 92 | $259.28 | |
| 83718 | <1% | 58 | $255.02 | |
| 82627 | <1% | 13 | $233.44 | |
| 81003 | <1% | 206 | $214.76 | |
| 84156 | <1% | 58 | $187.34 | |
| 84520 | <1% | 288 | $152.11 | |
| 84450 | <1% | 31 | $74.08 | |
| 84460 | <1% | 15 | $30.27 | |
| 82272 | <1% | 12 | $11.47 | |
| 84295 | <1% | 14 | $3.51 | |
| 82374 | 0% | 13 | $0.00 | |
| 82435 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBADALIAN, ZARA (OWNER)